- The shares of Atara Biotherapeutics Inc (NASDAQ: ATRA) have received a $27 price target from JPMorgan. These are the details.
The shares of Atara Biotherapeutics Inc (NASDAQ: ATRA) have received a $27 price target from JPMorgan. And JPMorgan analyst Anupam Rama increased the price target on Atara Biotherapeutics from $26 while maintaining an “Overweight” rating on the shares. Rama adjusted the rating following a conversation with the company CEO.
Rama is seeing a $2.5 billion-$3 billion peak worldwide opportunity for ATA188 in the primary and secondary progressive forms of multiple sclerosis. And Rama assumes a potential launch to start in 2027 with the current expectation that a full Phase 3 trial begins in the 2023/2024 timeframe.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.
